Skip to content
zameds

Melatonin (Cadiatev)

Melatonin

Teva Pharmaceuticals (Pty) Ltd

Registration

Applicant
Teva Pharmaceuticals (Pty) Ltd
Certificate holder
Teva Pharmaceuticals (Pty) Ltd
Registrations
1

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Cadiatev

EACH TABLET CONTAINS MELATONIN 2,0 mg

2 mgProlonged-release tablets.56038956/2.2/0389Approved 30 October 2024RegisteredNot determinedPIPIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Melatonin

    • except when used for the treatment of desyncronosis (jet-lag) in doses not exceeding 6 milligrams daily. (S2).

    Consolidated Schedules 06 July 2026, lines 7043 to 7044

  • S2: Melatonin

    • when used for the treatment of desyncronosis (jet-lag) in doses not exceeding 6 milligrams daily.

    Consolidated Schedules 06 July 2026, line 2282

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C13H16N2O2232.28 g/mol

N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide

Drag to rotate. Structure from PubChem CID 896.

SAHPRA documents

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles